Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Chief Financial Officer | August 14, 2026 | August 18, 2026 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Chief Financial Officer | January 31, 2019 | February 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korsana Biosciences, Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 25,018 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Exercise / conversion · Acquired 25,000 · Balance 25,018 F1: The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price. |
| Option to PurchaseSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2035-08-06 | Direct | 0 |
Reported balance
After 2026-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-14 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price.
Scholar Rock Holding Corp
Report date January 31, 2019 · Filed February 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.11 · Expires 2029-01-31 | Direct | 56,000 |
Reported balance
After 2019-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-31 · Grant · Acquired 56,000 · Balance 56,000 F1: This option vests quarterly over four (4) years, with the first quarterly amount vesting on March 31, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests quarterly over four (4) years, with the first quarterly amount vesting on March 31, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 18, 2026 21:27 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | Exercise / conversionOption to Purchase · Derivative | 25,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001193125-26-355721 · ownership.xml · derivative · entry 2 CHICKO RHONDA M. · CIK 0001740376 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2035-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price. F1 · derivative.exercise_date: The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 21:27 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | Exercise / conversionCommon Stock, no par value | 25,000 | $2.36 | $58,875.00 |
DisclosureSEC source: 0001193125-26-355721 · ownership.xml · nonDerivative · entry 1 CHICKO RHONDA M. · CIK 0001740376 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 20:05 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0000950170-25-106532 · ownership.xml · derivative · entry 1 CHICKO RHONDA M. · CIK 0001740376 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-08-06 F1 · derivative.exercise_date: The Reporting Person was granted an option to purchase up to 25,000 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan. These 25,000 shares vest as follows: (i) 8,750 shares are immediately exercisable, and (ii) the remaining 16,250 shares vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remains as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. Read SEC document |
| January 31, 2019 Filed Feb 5, 2019 00:36 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $15.11 | $0.00 |
DisclosureSEC source: 0001104659-19-005621 · a4.xml · derivative · entry 1 CHICKO RHONDA M. · CIK 0001740376 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2029-01-31 F1 · derivative.exercise_date: This option vests quarterly over four (4) years, with the first quarterly amount vesting on March 31, 2019. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:42 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 15,208 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-18-037316 · a4.xml · derivative · entry 1 CHICKO RHONDA M. · CIK 0001740376 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,208 Underlying: Common Stock · 15,208 shares Expires 2028-05-23 F1 · derivative.exercise_date: This option was granted on May 23, 2018 and following the closing of the Issuer's initial public offering on May 29, 2018, the vesting period for the stock option commenced and the stock option shall vest and become exercisable in 16 equal quarterly installments with the first quarterly amount to vest on August 29, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.